Monogenic Diseases: PKU and Galactosemia

Monogenic Diseases Overview

  • Focus on two well-known monogenic diseases:
    • Phenylketonuria (PKU)
    • Galactosemia

Phenylketonuria (PKU)

  • Definition: PKU is a recessive trait; a mutation in an enzyme causing loss of function, leading to metabolic issues.
  • Gene Involved: Phenylalanine Hydroxylase (PAH)
    • Function: Converts phenylalanine to tyrosine by adding a hydroxyl group.
  • Location: Enzyme is expressed in the liver.
  • Impact on Body:
    • Tyrosine is vital for protein synthesis and neurotransmitter production (e.g., serotonin).
    • Lack of tyrosine leads to neurological defects and insufficient neurotransmitter production.
    • Accumulation of phenylalanine in blood due to enzyme mutation can cross the blood-brain barrier, causing further neurologic issues.
Neurological Effects
  • Accumulating phenylalanine leads to:
    • Reduced myelination of neurons, affecting signal transmission.
    • Competition for transporters among amino acids: excess phenylalanine saturates transporters, reducing transport of necessary amino acids like tryptophan and tyrosine.
    • In fetuses, maternal PKU can lead to similar defects in offspring.
Diagnosis and Testing
  • Easily diagnosed through a blood sample rather than liver biopsy.
  • Tests for elevated levels of phenylalanine in blood.
Treatment Strategies
  • Diet Management:
    • Initiating a low-phenylalanine diet at newborn screening can significantly reduce risks of neurological damage.
    • Specialized medical formulas can be prescribed.
    • Lifelong adherence to low-protein diets is essential.
    • Need to supplement vitamins and minerals due to dietary restrictions.
  • Medications and New Treatments:
    • Recent drugs may assist in treatment; however, dietary intervention remains the most effective approach.
Historical Context
  • PKU discovered in the 1930s—early diagnosis linked to a musty odor in urine (indicative of phenylalanine derivatives).
  • Shift to dietary diagnosis and screening began in the 1960s with advancements in genetic understanding.

Galactosemia

  • Definition: A condition related to galactose metabolism, caused by mutation in the GALT enzyme.
  • Gene Involved: Galactose-1-phosphate uridyltransferase (GALT).
  • Symptoms and Diagnosis:
    • Similar to PKU, symptoms include digestive issues, diarrhea, and vomiting after lactose consumption.
    • Bilateral symptoms in newborns leading to poor weight gain; diagnosed through blood tests and newborn screening.
Metabolic Pathway Overview
  • Galactose Metabolism:
    • Galactose is derived from lactose (milk sugar)—when not metabolized properly, it accumulates and causes toxicity.
    • Involves conversion to glucose via GALT; if the enzyme is ineffective, toxic derivatives accumulate.
Treatment Considerations
  • Dietary Restrictions:
    • Lifelong avoidance of galactose, mainly through elimination of dairy and lactose-containing products.
    • Practicality of avoidance is easier compared to PKU as fewer foods contain galactose.
Nutritional Implications and Social Factors
  • Avoiding milk leads to nutrient deficiencies (e.g., calcium) and necessitates supplementation.
  • Psychological and social challenges arise from dietary restrictions, affecting the quality of life.

Conclusion

Both PKU and galactosemia are critical monogenic diseases with significant neurological and metabolic consequences. Early diagnosis through newborn screening and dietary management is vital in preventing severe complications. Social factors also play a crucial role in the lives of affected individuals, necessitating not only medical but also psychological support.